GGrantIndex
Sort

82,697 grants matching vaccine development

Development of a COVID Vaccine Model in NHP

$845,146
Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

Ion Channel Assay for Identifying Influenza Therapeutics

$845,142
Benjamin Jacob Doranz · Integral Molecular · R01 · FY2006 · AI

Development of vaccination strategies to elicit broadly protective immunity against influenza

$845,133
Jeffrey Victor Ravetch · Rockefeller University · R01 · FY2025 · AI

Structure-based design of coronavirus subunit vaccines

$845,133
Lanying Du · New York Blood Center · R01 · FY2019 · AI

Host Immune Responses to Antigens of Malaria Parasites

$845,075
Carole Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI

Immune correlates of tuberculosis and non-tuberculosis infectious morbidity in Southern African HIV-exposed, uninfected infants.

$845,032
Kathleen Powis · Massachusetts General Hospital · R01 · FY2023 · AI

NIH Director's Pioneer Award

$845,000
Evgeny Nudler · New York University School Of Medicine · DP1 · FY2006 · OD

NIH Director's Pioneer Award

$845,000
Evgeny Nudler · New York University School Of Medicine · DP1 · FY2007 · OD

Development of the Next Generation of Conjugate Vaccines

$844,945
Luc Teyton · Scripps Research Institute, The · R01 · FY2020 · AI

BIOMEDICAL RESEARCH INFRASTRUCTURE AT ALABAMA STATE UNI*

$844,926
Kennedy S Wekesa · Alabama State University · P20 · FY2007 · MD

Host control in Coccidioidomycosis

$844,908
University Of Arizona · P01 · FY2004 · AI

Rational design and evaluation of novel mRNA vaccines against MERS-CoV

$844,900
Lanying Du · New York Blood Center · R01 · FY2018 · AI

Cerebrospinal fluid (CSF) and peripheral markers of the neuropsychiatric sequelae of COVID-19: The Generation C-SF pregnancy study

$844,866
Maria De Las Mercedes Perez Rodriguez · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · MH

Development of an oral liver-targeted prime-and-trap malaria vaccine

$844,865
Sean C Murphy · University Of Washington · U01 · FY2022 · AI

Cerebrospinal fluid (CSF) and peripheral markers of the neuropsychiatric sequelae of COVID-19: The Generation C-SF pregnancy study

$844,801
Maria De Las Mercedes Perez Rodriguez · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · MH

Cerebrospinal fluid (CSF) and peripheral markers of the neuropsychiatric sequelae of COVID-19: The Generation C-SF pregnancy study

$844,677
Maria De Las Mercedes Perez Rodriguez · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · MH

Development of a pre-erythrocytic P. vivax vaccine to prevent clinical relapse

$844,617
D. Noah Sather · Seattle Children'S Hospital · R01 · FY2019 · AI

Food & Waterborne Diseases Integrated Research Network

$844,557
Yrjo Grohn · Cornell University · N01 · FY2009 · AI

Development of an mRNA-Based Therapeutic HIV/AIDS Vaccine

$844,491
Afamefuna Okoye · Oregon Health & Science University · R01 · FY2021 · AI

Discovery and development of broad spectrum anti-flaviviral drugs

$844,425
Mariano A. Garcia-Blanco · Duke University · R01 · FY2011 · AI

The effectiveness of screening women with lower genital tract neoplasia or cancers for anal cancer precursors

$844,362
Keith Magnus Sigel · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA

Mosquito SAMSP1 and SAMSP2 influence the initial stage of Plasmodium infection of mice

$844,320
Erol Fikrig · Yale University · R01 · FY2021 · AI

Development of Viral Vaccines against Sarbecoviruses and Merbecoviruses

$844,055
Michael S. Diamond · Washington University · P01 · FY2025 · AI

Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection

$844,040
Ada S Cowan · Metallopharm, Llc · R44 · FY2011 · AA

Elucidating the role of TSR glycosylation in Plasmodium parasites

$844,019
Kristian Edward Swearingen · Institute For Systems Biology · R01 · FY2022 · AI